Finance
DNA-focused biotechnology company reports 2005 first quarter financial results
Published in AIDS Weekly, May 23rd, 2005
The consolidated net loss was $3.6 million, or $0.14 per share, as compared to a net loss of $2.9 million, or $0.12 per share, in the same period of 2004. At March 31, 2005, the company had cash, cash equivalents, investments and interest receivable of $30.0 million.
Revenues for the first quarter of 2005 were $256,000 as compared to first quarter 2004 revenues of $811,000. First quarter 2005 revenues were from Sangamo's enabling technology research agreements, federal government research grants and human therapeutics collaborations. Revenues in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-05-23)
More Articles from AIDS Weekly
- HIV-2 Exposure
High HIV-2-specific T cell activity in HIV-2-exposed uninfected/infected persons - HIV/AIDS Drug Development
Molecular modeling reveals new HIV-1 IN binding site for nucleotide inhibitor - HIV/AIDS Surveillance
"Detuned" HIV immunoassay detects infections missed by surveillance methods - HIV/AIDS Vaccine
T cell vaccine might work against high- but not low-dose HIV exposure - Business & Finance
COLD-EEZE maker reports financial results - Business & Finance
Pharmaceutical company reports first quarter 2005 financial results - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
